AAPL 169.38 -1.9167% MSFT 414.58 0.2273% GOOG 156.0 -0.2111% GOOGL 154.4 -0.297% AMZN 183.32 -0.1634% NVDA 874.15 1.6442% META 499.76 -0.094% TSLA 157.11 -2.7062% TSM 139.8 -0.2426% LLY 746.74 -0.5368% V 271.35 0.0258% AVGO 1329.06 1.4016% JPM 180.8 -1.1428% UNH 468.89 5.2196% NVO 123.45 -0.3632% WMT 59.84 -0.1502% LVMUY 172.32 3.093% XOM 118.62 -0.8857% LVMHF 855.05 1.58% MA 459.82 0.0065%
Last update at 2024-04-16T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -62.31700M | -49.24100M | -46.79800M | -59.00600M | -51.15300M |
| Minority interest | - | - | - | - | - |
| Net income | -63.37000M | -53.49500M | -49.20800M | -63.11200M | -51.15300M |
| Selling general administrative | 30.62M | 28.53M | 21.29M | 27.30M | 25.70M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1.17M | 7.36M | -3.15000M | -8.42800M | -4.90400M |
| Reconciled depreciation | 2.27M | 2.54M | 3.16M | 3.64M | 2.45M |
| Ebit | -55.51000M | -42.97300M | -41.35600M | -52.05800M | -46.92000M |
| Ebitda | -55.47100M | -42.65500M | -41.29400M | -51.65800M | -44.47100M |
| Depreciation and amortization | 0.04M | 0.32M | 0.06M | 0.40M | 2.45M |
| Non operating income net other | - | - | 0.09M | 0.40M | 0.62M |
| Operating income | -55.51000M | -42.97300M | -41.35600M | -52.05800M | -45.09000M |
| Other operating expenses | 77.81M | 71.03M | 59.49M | 60.39M | 55.59M |
| Interest expense | 6.08M | 6.59M | 5.50M | 7.35M | 6.68M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.00800M | 0.11M | 0.01M | 7.35M | 6.68M |
| Net interest income | -6.07600M | -6.47400M | -5.50400M | -7.34800M | -6.68200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.05M | 4.25M | 2.41M | 4.11M | 0.62M |
| Total revenue | 22.30M | 28.06M | 18.13M | 8.34M | 10.50M |
| Total operating expenses | 56.68M | 50.33M | 38.21M | 43.63M | 40.19M |
| Cost of revenue | 21.14M | 20.70M | 21.28M | 16.76M | 15.40M |
| Total other income expense net | -6.80700M | -6.26800M | -5.44200M | -6.94800M | 0.62M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -62.00300M | -49.24100M | -46.79800M | -59.00600M | -51.15300M |
| Net income applicable to common shares | -62.64700M | -49.24100M | -46.79800M | -59.00600M | -51.15300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 34.39M | 60.54M | 79.08M | 28.49M | 64.31M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.58M | 3.11M | 2.66M | 1.44M | 1.34M |
| Total liab | 74.36M | 73.44M | 70.35M | 62.49M | 52.92M |
| Total stockholder equity | -39.96900M | -12.90300M | 8.73M | -34.00500M | 11.39M |
| Deferred long term liab | - | - | 0.10M | - | 0.49M |
| Other current liab | 7.69M | 7.16M | 6.36M | 13.63M | 8.21M |
| Common stock | 0.00800M | 0.17M | 0.15M | 0.05M | 0.04M |
| Capital stock | 0.00800M | 0.17M | 0.15M | 0.05M | 0.04M |
| Retained earnings | -534.53300M | -472.21600M | -422.97500M | -376.17700M | -317.17100M |
| Other liab | 4.90M | 4.61M | 4.78M | 0.05M | 0.62M |
| Good will | - | - | - | - | - |
| Other assets | 1.69M | 1.70M | 0.69M | 0.39M | 0.39M |
| Cash | 10.33M | 22.25M | 16.79M | 11.03M | 50.80M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 10.51M | 11.69M | 9.80M | 60.57M | 52.30M |
| Current deferred revenue | 0.17M | 0.52M | 0.23M | 0.28M | 0.70M |
| Net debt | 48.89M | 34.90M | 38.98M | 33.74M | -7.67200M |
| Short term debt | 1.35M | 1.17M | 1.15M | 42.90M | 42.64M |
| Short long term debt | - | - | - | 42.90M | 42.37M |
| Short long term debt total | 59.22M | 57.15M | 55.77M | 44.77M | 43.13M |
| Other stockholder equity | 494.56M | 459.15M | 431.55M | 342.12M | 339.82M |
| Property plant equipment | 13.27M | 14.44M | 14.80M | 5.84M | 7.32M |
| Total current assets | 19.42M | 44.39M | 53.58M | 18.89M | 56.61M |
| Long term investments | - | 0.00000M | 10.00M | - | - |
| Net tangible assets | -39.96900M | -12.90300M | 8.73M | -32.08600M | 11.52M |
| Short term investments | 0.00000M | 10.00M | 25.40M | - | - |
| Net receivables | 2.16M | 5.13M | 5.10M | 2.83M | 1.79M |
| Long term debt | 49.65M | 47.79M | 45.23M | - | - |
| Inventory | 4.35M | 3.91M | 3.64M | 3.60M | 2.68M |
| Accounts payable | 1.30M | 2.83M | 2.06M | 3.75M | 0.74M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -0.00400M | 0.00900M | -13.23600M | -11.30700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.15M | 0.05M | 0.04M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -422.97500M | -376.17700M | -317.17100M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.69M | 1.70M | 0.69M | 0.39M | 0.39M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 14.97M | 16.14M | 25.49M | 9.59M | 7.70M |
| Capital lease obligations | 9.57M | 9.36M | 10.53M | 3.86M | 0.76M |
| Long term debt total | - | - | 45.23M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 9.66M | 25.25M | -35.46100M | -0.76100M | -0.59300M |
| Change to liabilities | 0.00000M | 0.65M | -1.32900M | 6.67M | -0.15800M |
| Total cashflows from investing activities | - | 24.79M | -36.26100M | -0.76100M | -0.59300M |
| Net borrowings | - | - | - | -0.88200M | -1.54700M |
| Total cash from financing activities | 29.05M | 20.54M | 85.61M | 6.35M | 49.66M |
| Change to operating activities | - | -0.84900M | -3.37600M | 1.35M | -0.84900M |
| Net income | -62.00300M | -49.24100M | -46.79800M | -59.00600M | -51.15300M |
| Change in cash | -11.91600M | 6.45M | 6.13M | -39.77200M | 8.93M |
| Begin period cash flow | 23.80M | 17.34M | 11.21M | 50.98M | 42.06M |
| End period cash flow | 11.88M | 23.80M | 17.34M | 11.21M | 50.98M |
| Total cash from operating activities | -50.62900M | -38.87400M | -43.21500M | -45.36100M | -40.13800M |
| Issuance of capital stock | 29.46M | 19.97M | 85.31M | 6.65M | 51.20M |
| Depreciation | 2.27M | 2.54M | 3.16M | 3.64M | 2.45M |
| Other cashflows from investing activities | - | - | 0.00400M | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.94900M | -1.94000M | 0.44M | -0.91400M | -1.08900M |
| Change to account receivables | 2.97M | -0.03500M | -2.27400M | -1.03900M | -1.31900M |
| Sale purchase of stock | -0.33000M | - | - | 0.58M | 1.97M |
| Other cashflows from financing activities | 0.22M | 0.57M | 0.30M | 0.58M | -0.59300M |
| Change to netincome | - | 10.00M | 6.96M | 8.14M | 12.51M |
| Capital expenditures | 0.34M | 0.46M | 0.80M | 0.76M | 0.59M |
| Change receivables | - | - | -2.27400M | -1.03900M | -1.31900M |
| Cash flows other operating | - | - | -1.52300M | -1.41200M | -1.37700M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 6.13M | -39.77200M | 8.93M |
| Change in working capital | -0.50300M | -2.17100M | -6.53800M | 1.86M | -3.94300M |
| Stock based compensation | 6.49M | 7.09M | 3.91M | 5.46M | 9.90M |
| Other non cash items | 3.11M | 3.93M | 3.31M | 2.41M | 2.00M |
| Free cash flow | -50.96800M | -39.33400M | -44.01900M | -46.12200M | -40.73100M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TTOO T2 Biosystms Inc |
0.06 2.02% | 3.03 | - | - | 1.79 | 14.50 | 4.24 | -1.1137 |
| TMO Thermo Fisher Scientific Inc |
-3.32 0.60% | 554.55 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
0.68 0.28% | 240.34 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IDXX IDEXX Laboratories Inc |
-1.72 0.35% | 489.57 | 55.57 | 53.76 | 12.50 | 34.56 | 12.72 | 38.21 |
| IQV IQVIA Holdings Inc |
-2.02 0.87% | 229.14 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
101 Hartwell Avenue, Lexington, MA, United States, 02421
| Name | Title | Year Born |
|---|---|---|
| Mr. John J. Sperzel III, B.Sc. | Pres, CEO & Chairman | 1963 |
| Mr. Michael Terrence Gibbs Esq. | Sr. VP & Gen. Counsel | 1971 |
| Mr. Alec J. Barclay | Sr. VP | 1980 |
| Mr. John M. Sprague CPA | Chief Financial Officer | 1958 |
| Ms. Kelley J. Morgan | Chief People Officer | 1976 |
| Dr. Aparna Jha Ahuja M.D. | Chief Medical Officer & Chairman of Scientific Advisory Board | 1967 |
| Mr. Brett A. Giffin | Chief Commercial Officer | 1959 |
| Dr. Roger Smith Ph.D. | Sr. VP of Science R&D | 1965 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...